Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacogenetics of acute lymphoblastic leukemia treatment response

Pharmacogenetics of acute lymphoblastic leukemia treatment response Acute lymphoblastic leukemia is the most common childhood cancer and generally has a favorable prognosis. However, some children experience disease relapse or clinically important treatment-related toxicities. Although some of the risk factors for treatment failure and toxicity are known, these risk factors still imperfectly predict relapse and toxicity. Genetic variation in the enzymes of the folic acid cycle, one-carbon transfer, immune surveillance, drug metabolism and transport may determine some of the variability in treatment response. This review summarizes the present published literature on the role of these genetic polymorphisms in determining treatment response. Despite these recent advances, further work is needed to develop clinically useful genetic predictors of leukemia treatment response. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Expert Opinion on Pharmacotherapy Taylor & Francis

Pharmacogenetics of acute lymphoblastic leukemia treatment response

14 pages

Loading next page...
 
/lp/taylor-francis/pharmacogenetics-of-acute-lymphoblastic-leukemia-treatment-response-i5fqSHOyzg

References (91)

Publisher
Taylor & Francis
Copyright
© Informa UK Ltd
ISSN
1744-7666
eISSN
1465-6566
DOI
10.1517/14656566.8.15.2519
Publisher site
See Article on Publisher Site

Abstract

Acute lymphoblastic leukemia is the most common childhood cancer and generally has a favorable prognosis. However, some children experience disease relapse or clinically important treatment-related toxicities. Although some of the risk factors for treatment failure and toxicity are known, these risk factors still imperfectly predict relapse and toxicity. Genetic variation in the enzymes of the folic acid cycle, one-carbon transfer, immune surveillance, drug metabolism and transport may determine some of the variability in treatment response. This review summarizes the present published literature on the role of these genetic polymorphisms in determining treatment response. Despite these recent advances, further work is needed to develop clinically useful genetic predictors of leukemia treatment response.

Journal

Expert Opinion on PharmacotherapyTaylor & Francis

Published: Oct 1, 2007

Keywords: acute lymphoblastic leukemia; outcome; pharmacogenetic; single nucleotide polymorphism

There are no references for this article.